Akers Biosciences, Inc. (NASDAQ: AKER) has closed a registered direct offering of 1,366,856 shares at $3.53 per share, generating approximately $4.8 million in gross proceeds. H.C. Wainwright & Co. was the exclusive placement agent. This offering was conducted under an effective shelf registration statement. Akers is focusing on developing a coronavirus vaccine candidate and other rapid health information technologies, while also exploring opportunities in the hemp and cannabinoid sectors.
Akers Biosciences (NASDAQ: AKER) announced a registered direct offering of 1,366,856 shares at $3.53 per share, totaling approximately $4.8 million in gross proceeds. The offering is set to close around May 18, 2020, subject to customary conditions. H.C. Wainwright & Co. is the exclusive placement agent. This stock sale is registered under a previously filed Form S-3 registration statement. The company focuses on rapid health technologies and is pursuing a license for a coronavirus vaccine candidate.
Akers Biosciences (NASDAQ: AKER) announced a significant milestone in its partnership with Premas Biotech, revealing that Premas has successfully completed its COVID-19 vaccine prototype. This development includes obtaining transmission electron microscopic (TEM) images of the virus-like particles (VLP) assembled in yeast, marking a first in the VLP of SARS-CoV-2. Both companies are now in discussions with regulatory authorities in India and the U.S. to advance their regulatory strategy, while large-scale production studies are underway.